CRYSTAL STRUCTURE OF C<sub>17</sub>H<sub>20</sub>FN<sub>3</sub>O·CuBr·H<sub>2</sub>O
A new compound C<sub>17</sub>H<sub>20</sub>FN<sub>3</sub>O·CuBr·H<sub>2</sub>O is synthesized in the crystal form, where C<sub>17</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub> (CfH, ciprofloxacin) is 4-oxo-7-(1-piperazinyl)-6-fluoro-1-cyclopropyl-1,4-dihydroquinoline-3-carboxylic acid. Crystallographic data of ciprofloxacinium tetrabromocuprate(II) monohydrate, C<sub>17</sub>H<sub>22</sub>Br<sub>4</sub>CuFN<sub>3</sub>O<sub>4</sub>: <i>a</i> = 8.214(1) Å, <i>b</i> = 10.781(2) Å, <i>с</i> = 13.703(2) Å, α = 85.144(2)°, β = 79.119(2)°, γ = 84.018(2)°, <i>V</i> = 1182.5(4) Å<sup>3</sup>, space group, <i>Z</i> = 2. Supramolecular architecture of the crystal differs from that established for C<sub>17</sub>H<sub>20</sub>FN<sub>3</sub>O·CuCl·H<sub>2</sub>O by the absence of π-π interactions of the aromatic rings of CfH ions and also the structural motifs formed by intermolecular hydrogen bonds.